/PRNewswire/ Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet.
In light of the incentive program adopted by the annual general meeting of Medivir AB on 4 May 2023 , it is today announced that the board of directors of Medivir has resolved on a share issue of. | May 16, 2023
On 4th May 2023, Medivir AB (publ) ("the Company") issued a press release with
information that the B-shares will be converted into ordinary shares. The last
day of trading in the Company's B-shares will
/PRNewswire/ Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical presence of.
/PRNewswire/ The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of association, whereby the.